These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2908754)

  • 1. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid.
    Nielsen OH; Verspaget HW; Elmgreen J
    Aliment Pharmacol Ther; 1988 Jun; 2(3):203-11. PubMed ID: 2908754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible mode of action of 5-aminosalicylic acid.
    Peskar BM; Dreyling KW; May B; Schaarschmidt K; Goebell H
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):51S-56S. PubMed ID: 2891468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes.
    Horn H; Preclik G; Stange EF; Ditschuneit H
    Scand J Gastroenterol; 1991 Aug; 26(8):867-79. PubMed ID: 1685260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells.
    Schmidt C; Fels T; Baumeister B; Vetter H
    Curr Med Res Opin; 1996; 13(7):417-25. PubMed ID: 8862941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
    Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.
    Greenfield SM; Punchard NA; Thompson RP
    Gut; 1991 Oct; 32(10):1156-9. PubMed ID: 1683330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scavenger effect of sulphasalazine (SASP), 5-aminosalicylic acid (5-ASA), and olsalazine (OAZ).
    Gionchetti P; Guarnieri C; Campieri M; Belluzzi A; Brignola C; Iannone P; Miglioli M; Barbara L
    Gut; 1990 Jun; 31(6):730-1. PubMed ID: 1974235
    [No Abstract]   [Full Text] [Related]  

  • 9. Leukotrienes in Crohn's disease: effect of sulfasalazine and 5-aminosalicylic acid.
    Dreyling KW; Hoppe U; Peskar BA; Schaarschmidt K; Peskar BM
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():339-43. PubMed ID: 2889333
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid.
    Peskar BM; Dreyling KW; Peskar BA; May B; Goebell H
    Agents Actions; 1986 Jun; 18(3-4):381-3. PubMed ID: 2875632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis.
    Eliakim R; Karmeli F; Chorev M; Okon E; Rachmilewitz D
    Scand J Gastroenterol; 1992 Nov; 27(11):968-72. PubMed ID: 1455196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
    Kles KA; Vavricka SR; Turner JR; Musch MW; Hanauer SB; Chang EB
    Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
    Tornhamre S; Edenius C; Smedegård G; Sjöquist B; Lindgren JA
    Eur J Pharmacol; 1989 Oct; 169(2-3):225-34. PubMed ID: 2572437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
    Rask-Madsen J; Bukhave K; Laursen LS; Lauritsen K
    Agents Actions; 1992; Spec No():C37-46. PubMed ID: 1359745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs. exogenous arachidonic acid.
    Allgayer H; Stenson WF
    Immunopharmacology; 1988; 15(1):39-46. PubMed ID: 2896181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease.
    Schmidt C; Kosché E; Baumeister B; Vetter H
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):865-9. PubMed ID: 8574719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.
    Szumlanski CL; Weinshilboum RM
    Br J Clin Pharmacol; 1995 Apr; 39(4):456-9. PubMed ID: 7640156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat.
    Gálvez J; Garrido M; Merlos M; Torres MI; Zarzuelo A
    Br J Pharmacol; 2000 Aug; 130(8):1949-59. PubMed ID: 10952687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.